Amundi’s Janux Therapeutics JANX Stock Holding History

Amundi’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,154	Closed	-$31.1K	–	1924
2025 Q1	$31.1K	Buy	1,154 +21	+2%	+$792	﹤0.01%	1840
2024 Q4	$57.6K	Sell	1,133 -7,238	-86%	-$383K	﹤0.01%	1838
2024 Q3	$376K	Sell	8,371 -1,038	-11%	-$45.2K	﹤0.01%	1496
2024 Q2	$362K	Buy	+9,409	New	+$442K	﹤0.01%	1417

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Amundi's JANX Position: Q2 2025 in Review

Amundi sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 1,154 shares — an estimated $31.1K sold.

Amundi first reported a position in JANX in Q2 2024 and held it in 4 quarters. The position peaked at $376K in Q3 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

Amundi reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
Amundi sold 1,154 Janux Therapeutics shares in Q2 2025, an estimated $31.1K.
Amundi first reported a position in Janux Therapeutics in Q2 2024 and held it in 4 quarters.
Amundi's Janux Therapeutics position peaked at $376K in Q3 2024.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.